Population pharmacokinetics of micafungin over repeated doses in critically ill patients: a need for a loading dose?. (12th August 2020)

• Record Type: Journal Article
• Authors: Kapralos, Iasonas; Mainas, Efstratios; Neroutsos, Efthymios; Apostolidi, Stella; Siopi, Maria; Apostolopoulou, Olympia; Dimopoulos, George; Sambatakou, Helen; Valsami, Georgia; Meletiadis, Joseph; Dokoumetzidis, Aristides
• Is Part Of: Journal of pharmacy and pharmacology. Volume 72:Number 12(2020)
• Page Start: 1750
• Page End: 1760
• Publication Date: 2020-08-12
• Subjects: echinocandines -- Infectious diseases -- micafungin Pharmacokinetic-Pharmacodynamic -- Monte Carlo simulation -- Population pharmacokinetics; Pharmacy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/jphp.13353
• Languages: English
• ISSNs: 0022-3573

Abstract

Abstract: Objectives: To study the population pharmacokinetics of micafungin in critically ill patients, evaluate and optimize dosage regimens. Methods: An HPLC–fluorescence bioassay for micafungin was developed, fully validated and applied to a pharmacokinetic study conducted in 14 ICU patients. Dense blood sampling was performed from days 1 to 7. A population pharmacokinetic model accounting for interindividual (IIV) and interoccasion variability (IOV) of the PK parameters was developed. Simulations were performed to estimate the probability of target attainment (PTA) for several dosing regimens. Key findings: A two-compartment pharmacokinetic model best described the data, with population clearance CL = 1.31 L/h and central volume V1 = 14.2 L. The relatively high IOV observed (45% for CL, 27% for V1) sets limits for the dose individualization in this population. The low PTA on the first day of treatment suggests the need of a loading dose. PTA and CFR estimates show that the current micafungin dosage may be insufficient for the treatment of borderline susceptible Candida strains. Conclusions: A loading dose of up to 300 mg of micafungin is needed for the treatment of invasive candidiasis in ICU patients while a maintenance dose of up to 200 mg can be considered in empirical antifungal treatment.